A research team at Hannover Medical School has identified Adhibin, a synthetic compound that inhibits cancer metastasis by targeting the Rho GTPase signaling pathway. Unlike conventional cancer treatments that kill both healthy and cancerous cells, Adhibin paralyzes tumor cells, preventing their migration and attachment to other tissues without significant toxicity.

The study, published in Nature Communications, highlights how Adhibin interferes with myosin motor proteins, which regulate Rho GTPases—molecular switches crucial for cell movement and metastasis. By blocking these pathways, Adhibin stops tumor cells from spreading, effectively “freezing” their mobility.

Initial experiments in tumor cells, organoid models and xenograf in vivo models demonstrated that when Adhibin was introduced, cell migration ceased. Upon removal of the compound, tumor cells regained mobility, confirming its reversible and targeted action.

Researchers have developed multiple Adhibin variants and plan to conduct preclinical studies to assess their safety and efficacy. If successful, Adhibin could revolutionize anti-metastatic treatments, offering a powerful tool to complement existing cancer therapies and prevent the deadly spread of tumors.

Source.